

IMMUCELL CORP /DE/  
Form 8-K  
August 11, 2016  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report: August 11, 2016  
(Date of earliest event reported)

ImmuCell Corporation  
(Exact name of registrant as specified in its charter)

DE 001-12934 01-0382980  
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)

56 Evergreen Drive, Portland, Maine 04103  
(Address of principal executive offices) (Zip Code)

207-878-2770  
(Registrant's telephone number, including area code)

Not Applicable  
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

[Press Release of ImmuCell Corporation dated August 11, 2016](#)

---

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ImmuCell Corporation

Dated: August 11, 2016

By: /s/ Michael F. Brigham  
Michael F. Brigham  
&nbsp;    President, Chief Executive Officer and Principal Financial  
Officer

---

Exhibit Index

Exhibit No. Description

99.1 Press Release of ImmuCell Corporation dated August 11, 2016